Recombinant Human TREM2 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human TREM2 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to bind fluorescein-conjugated E. coli Bioparticles. The ED₅₀ for this effect is 0.04-0.16 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived human TREM2 protein
  

  Human TREM-2 (His19 - Ser174) Accession # NP_061838.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: NP_061838.1
• N-terminal Sequence: His19
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: TREM2
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 44 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-65 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 300 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TREM2 Fc Chimera Protein, CF

• PLOSL2
• TREM2
• TREM-2
• Trem2a
• Trem2b
• Trem2c
• TREM-2triggering receptor expressed on myeloid cells 2a
• Triggering receptor expressed on monocytes 2
• triggering receptor expressed on myeloid cells 2

Background

TREM-2 (Triggering Receptor Expressed on Myeloid cells-2) is a 35 kDa type I transmembrane member of the TREM family and Ig superfamily (1). Mature human TREM-2  consists of a 156 amino acid (aa) extracellular domain (ECD) with one V-type Ig-like domain, a 21 aa transmembrane (TM) domain, and a 35 aa cytoplasmic tail (2). Within the ECD, human TREM-2 shares 73% and 74% aa sequence identity with mouse and rat TREM-2, respectively. Soluble forms of the TREM-2 ECD are generated by alternative splicing or proteolytic cleavage, and the cytoplasmic domain can be liberated by gamma-Secretase mediated intramembrane cleavage (3). A positively charged lysine within the transmembrane segment allows association with the signal adapter protein, DAP12 and inhibition of macrophage activation (4, 5). TREM-2 is expressed on macrophages, immature myeloid dendritic cells, osteoclasts, microglia, and adipocytes (5-9). It promotes the differentiation and function of osteoclasts, the production of inflammatory cytokines by adipocytes, insulin resistance, and the phagocytic clearance of bacteria (9-11). In the CNS, TREM-2 binds to ApoE, ApoA1, and ApoB and mediates the clearance of apoptotic neurons, amyloid plaques, and cell debris following demyelination (6-8, 12). TREM-2 also interacts with and modifies signaling through Plexin A1 on dendritic cells and osteoclasts (13). Mutations in TREM-2 or DAP12 are associated with the development of Alzheimer's disease and Nasu-Hakola disease (NHD/PLOSL) which is characterized by presenile dementia and bone cysts (14, 15). Soluble TREM-2 is elevated in cerebrospinal fluid of patients with active multiple sclerosis (MS), and TREM-2 blockade exacerbates disease symptoms in the experimental EAE model of MS (16, 17).

1. Painter, M.M. et al. (2015) Mol. Neurodegener. 10:43.
2. Bouchon, A. et al. (2000) J. Immunol. 164:4991.
3. Wunderlich, P. et al. (2013) J. Biol. Chem. 288:33027.
4. Hamerman, J. A. et al. (2006) J. Immunol. 177:2051.
5. Turnbull, I.R. et al. (2006) J. Immunol. 177:3520.
6. Takahashi, K. et al. (2005) J. Exp. Med. 201:647.
7. Atagi, Y. et al. (2015) J. Biol. Chem. 290:26043.
8. Wang, Y. et al. (2016) J. Exp. Med. 213:667.
9. Cella, M. et al. (2003) J. Exp. Med. 198:645.
10. Park, M. et al. (2015) Diabetes 64:117.
11. N'Diaye, E-N. et al. (2009) J. Cell Biol. 184:215.
12. Poliani, P.L. et al. (2015) J. Clin. Invest. 125:2161.
13. Takegahara, N. et al. (2006) Nat. Cell Biol. 8:615.
14. Colonna, M. and Y. Wang (2016) Nat. Rev. Neurosci. 17:201.
15. Paloneva, J. et al. (2002) Am. J. Hum. Genet. 71:656.
16. Piccio, L. et al. (2008) Brain 131:3081.
17. Piccio, L. et al. (2007) Eur. J. Immunol. 37:1290.

Publications for TREM2 (1828-T2)(2)

Publications using 1828-T2

• Yang, Y;Shi, G;Ge, Y;Huang, S;Cui, N;Tan, L;Liu, R;Yang, X; Accumulated BCAAs and BCKAs contribute to the HFD-induced deterioration of Alzheimer's disease via a dysfunctional TREM2-related reduction in microglial ?-amyloid clearance Journal of neuroinflammation 2024-12-23 [PMID: 39716292] (Bioassay, Human)
• Y Zhao, X Wu, X Li, LL Jiang, X Gui, Y Liu, Y Sun, B Zhu, JC Piña-Cresp, M Zhang, N Zhang, X Chen, G Bu, Z An, TY Huang, H Xu TREM2 Is a Receptor for ?-Amyloid that Mediates Microglial Function Neuron, 2018-03-07;97(5):1023-1031.e7. 2018-03-07 [PMID: 29518356] (Bioassay, Immunoprecipitation, Surface Plasmon Resonance (SPR, Human)

Bioinformatics

• Gene Symbol: TREM2
• Uniprot:
  • NP_061838.1(Human)